The Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT) is a trial to determine the clinical efficacy and safety of omalizumab (Xolair, Novartis) for children with severe atopic eczema. This evidence concerns the gene IGHE and atopic eczema.